Verification of a Proteomic Biomarker Panel to Diagnose Minor Stroke and Transient Ischaemic Attack: Phase 1 of SpecTRA, a Large Scale Translational Study.

Objective: To derive a plasma biomarker protein panel from a list of 141 candidate proteins which can differentiate transient ischaemic attack (TIA)/minor stroke from non-cerebrovascular (mimic) conditions in emergency department (ED) settings.Design: Prospective clinical study (#NCT03050099) with up to three timed blood draws no more than 36h following symptom onset. Plasma samples analysed by multiple reaction monitoring-mass spectrometry (MRM-MS).Participants: Totally 545 participants suspected of TIA enrolled in the EDs of two urban medical centres.Outcomes: 90-day, neurologist-adjudicated diagnosis of TIA informed by clinical and radiological investigations.Results: The final protein panel consists of 16 proteins whose patterns show differential abundance between TIA and mimic patients. Nine of the proteins were significant univariate predictors of TIA [odds ratio (95% confidence interval)]: L-selectin [0.726 (0.596-0.883)]; Insulin-like growth factor-binding protein 3 [0.727 (0.594-0.889)]; Coagulation factor X [0.740 (0.603-0.908)]; Serum paraoxonase/lactonase 3 [0.763 (0.630-0.924)]; Thrombospondin-1 [1.313 (1.081-1.595)]; Hyaluronan-binding protein 2 [0.776 (0.637-0.945)]; Heparin cofactor 2 [0.775 (0.634-0.947)]; Apolipoprotein B-100 [1.249 (1.037-1.503)]; and von Willebrand factor [1.256 (1.034-1.527)]. The scientific plausibility of the panel proteins is discussed.Conclusions: Our panel has the potential to assist ED physicians in distinguishing TIA from mimic patients.